Eisai Co., Ltd and nippon medac Co., Ltd. announced a manufacturing and marketing approval of Metoject Subcutaneous Injection (Methotrexate) from the Japanese Ministry of Health, Labour and Welfare for the treatment of rheumatoid arthritis.
Cumberland Pharmaceuticals Inc. announced the launch of RediTrex (methotrexate) injection which is designed for dosing accuracy for the subcutaneous administration of methotrexate in patients with arthritis and psoriasis.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 2738
Published Date: Jul 27, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The surge in the prevalence of rheumatoid arthritis and the increasing prevalence of cancer are the major factors driving the market growth.
The market is anticipated to attain a CAGR of 2.9% over the forecast period, i.e., 2022 â€“ 2031.
The major players in the market are Pfizer Inc., Azurity Pharmaceuticals, Inc., Cumberland Pharmaceuticals Inc., Inc, Teva Pharmaceuticals USA, Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, and Others
The cancer segment is anticipated to garner the largest market size by the end of 2031 and display significant growth opportunities.
The market in the North American region is projected to hold the largest market share by the end of 2031 and provide more business opportunities in the future.